Natural history of HBeAG-negative chronic hepatitis B

被引:0
|
作者
Ghany M.G. [1 ]
Liang T.J. [1 ]
机构
[1] Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892-1800
关键词
Chronic Hepatitis; Fulminant Hepatitis; HBeAg Seroconversion; Precore Variant; Negative Chronic Hepatitis;
D O I
10.1007/s11901-006-0020-1
中图分类号
学科分类号
摘要
Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B refers to an atypical presentation of chronic hepatitis B characterized by the absence of HBeAg but with clinical and histologic evidence of chronic hepatitis and the presence of ongoing viral replication. It Is caused by a variety of mutations affecting transcription and translation of the precore-core RNA, the most common being the precore and double core promoter mutations. They have a worldwide distribution and development of the precore variant is genotype dependent. These variants may present as fulminant hepatitis but more commonly present as asymptomatic hepatitis during the natural course of chronic infection. The most characteristic pattern is one of severe flares followed by remissions. Long-term response to therapy is poor. Copyright © 2006 by Current Science Inc.
引用
收藏
页码:27 / 32
页数:5
相关论文
共 50 条
  • [1] Methodological considerations in studying natural history of HBeAg-negative and -positive chronic hepatitis B
    Cai, Guohong
    Yin, Wen
    [J]. LIVER INTERNATIONAL, 2012, 32 (04) : 689 - 690
  • [2] Treatment of HBeAg-negative chronic hepatitis B
    Hadziyannis, SJ
    Papatheodoridis, GV
    Vassilopoulos, D
    [J]. SEMINARS IN LIVER DISEASE, 2003, 23 (01) : 81 - 88
  • [3] HBeAg-negative chronic hepatitis
    Ibragimova, MM
    Krel, PE
    Abdurakhmanov, DT
    [J]. TERAPEVTICHESKII ARKHIV, 2004, 76 (02): : 87 - 91
  • [4] Combination treatment in HBeAg-negative chronic hepatitis B
    Tziomalos, Konstantinos
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2009, 1 (01) : 43 - 47
  • [5] Management of patients with HBeAg-negative chronic hepatitis B
    Saikia, Nripen
    Talukdar, Rupjyoti
    Mazumder, Subhasish
    Khanna, Sudeep
    Tandon, Rakesh
    [J]. POSTGRADUATE MEDICAL JOURNAL, 2007, 83 (975) : 32 - 39
  • [6] Efficacy of lamivudine in HBeAg-negative chronic hepatitis B
    Rizzetto, M
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2002, 66 (04) : 435 - 451
  • [7] Progress in HBeAg-negative chronic hepatitis B therapy
    [J]. Nature Clinical Practice Gastroenterology & Hepatology, 2004, 1 (1): : 11 - 11
  • [8] Are Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B and HBeAg-Negative Chronic Hepatitis B Distinct Diseases?
    Nguyen, Mindie H.
    Keeffe, Emmet B.
    [J]. CLINICAL INFECTIOUS DISEASES, 2008, 47 (10) : 1312 - 1314
  • [9] Treatment of HBeAg-negative chronic hepatitis B with pegylated interferon
    Lampertico, Pietro
    Vigano, Mauro
    Colombo, Massimo
    [J]. LIVER INTERNATIONAL, 2011, 31 : 90 - 94
  • [10] HBeAg-negative chronic hepatitis B: From obscurity to prominence
    Manesis, Emanuel K.
    [J]. JOURNAL OF HEPATOLOGY, 2006, 45 (03) : 343 - 346